Smart Capital Traders
  • Politics
  • Investing
  • Latest News
  • Stocks

Smart Capital Traders

  • Politics
  • Investing
  • Latest News
  • Stocks
Stocks

Bristol Myers Squibb’s Rising SCTR Score: Seize the Moment to Invest?

by admin February 28, 2025
February 28, 2025
Bristol Myers Squibb’s Rising SCTR Score: Seize the Moment to Invest?

Bristol Myers Squibb (BMY) reported strong Q4 earnings earlier in February, and prospects remain strong for 2025, although it may face some headwinds. The recent earnings announcement for the company led to a pullback in the stock price; however, BMY is now showing signs of recovery and gaining some momentum.

The stock caught my interest when I ran my StockCharts Technical Rank (SCTR) scan on Thursday evening. An attractive price point and the recent strength of the Health Care sector enticed me to do a deeper dive into the stock’s charts.

The Health Care sector was in a steady downfall from September to December 2024. Bristol Myers Squibb (BMY) deviated from the downfall and trended higher during this time. The daily chart of BMY below shows the stock’s performance relative to the Health Care Select Sector SPDR Fund (XLV). Since September 30, 2024, BMY’s performance has outperformed XLV’s. Even during the February pullback, the stock was performing better than the Health Care sector.

FIGURE 1. DAILY CHART OF BRISTOL MYERS SQUIBB. The SCTR score has crossed 76, the MACD is crossing over into positive territory, and BMY is outperforming XLV.Chart source: StockCharts.com. For educational purposes.

The SCTR score in the upper panel didn’t display strength until November and, even though it crossed above 76, it didn’t go higher than 92. In late January, the SCTR score fell below the 76 level.

The following points are worth noting:

  • The stock price bounced off its 21-day exponential moving average (EMA) and 50-day SMA on Thursday.
  • The SCTR score has crossed above the 76 level.
  • Bristol Myers Squibb’s relative performance against XLV is at 21.31% and trending higher.
  • The moving average convergence/divergence (MACD) has crossed above its signal line and is very close to the zero line.

If BMY’s stock price continues to rise higher there could be an opportunity to add some positions of this stock. How high could the stock price go? The probability of BMY hitting its 52-week high is high, but, for a favorable risk-to-reward ratio, there needs to be strong upside momentum. The weekly chart below shows the stock has the potential to rise to around the $72 level.

FIGURE 2. WEEKLY CHART OF BRISTOL MYERS SQUIBB. A break above the upper Bollinger Band, rising RSI, and crossover of the stochastic oscillator point to further upside move in the stock price.Chart source: StockCharts.com. For educational purposes.

  • A break above the upper Bollinger Band® would be positive for the stock.
  • The relative strength index (RSI) is just shy of 60. A cross above 70 would confirm upside momentum.
  • Look for the %K line to cross over the %D line in the full stochastic oscillator (lower panel).

The bottom line: I’ll be monitoring Bristol Myers Squibb’s stock price closely. I’ve set an alert to notify me when the stock price crosses above $61. If the indicators in the daily chart still indicate buying pressure is strong and the trend is bullish, I’ll consider adding BMY to my portfolio.


The SCTR Scan

[country is US] and [sma(20,volume) > 100000] and [[SCTR.us.etf x 76] or [SCTR.large x 76] or [SCTR.us.etf x 78] or [SCTR.large x 78] or [SCTR.us.etf x 80] or [SCTR.large x 80]]



Disclaimer: This blog is for educational purposes only and should not be construed as financial advice. The ideas and strategies should never be used without first assessing your own personal and financial situation, or without consulting a financial professional.

previous post
Trump official blasts Washington Post for ‘fake news’ reporting about DOGE firings
next post
Bearish Signals & Risk Management: Protect Your Portfolio!

related articles

Silver Cross Index Tops Beneath Signal Line on...

March 29, 2025

Financials Primed to Beat Tech in December!

December 3, 2024

This Report Might Self Destruct in 5 Days

April 12, 2025

S&P 500 Sectors Play Musical Chairs: How To...

February 8, 2025

4 Scenarios for Nasdaq 100: Bullish Surge or...

March 18, 2025

Master the Market: A Guide to StockCharts’ New...

April 12, 2025

New US Tariffs and Intensifying US–China Trade War:...

April 13, 2025

Will Breadth Divergences Signal the End of the...

October 31, 2024

Spotting a Bullish Opportunity in Zscaler (ZS) with...

November 16, 2024

Three Behavioral Biases Impacting Your Portfolio Right Now

February 5, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Most Popular

    • 1

      Retraction of Forecast Financial Information Plus Announcement on New Metallurgical Testwork Results

      October 15, 2024
    • 2

      Bold Ventures Announces Final Closing of Non-Brokered Private Placement and Insider Subscriptions

      October 19, 2024
    • 3

      As North Korea, Iran and China support Russia’s war, is a ‘new axis’ emerging?

      October 25, 2024
    • 4

      Lode Gold Launches Exploration Program at One of the Largest Land Packages in New Brunswick

      October 19, 2024
    • 5

      Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

      October 31, 2024

    Categories

    • Investing (1,588)
    • Latest News (1,886)
    • Politics (1,954)
    • Stocks (625)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smartcapitaltraders.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smartcapitaltraders.com | All Rights Reserved